US › Healthcare

Alkermes Plc (ALKS)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$49.67+0.28%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$496.0M
Revenue YoY
+27.0%
Net profit
$501,000
Profit YoY
-99.4%
EPS
$0.52
EPS estimate
$-0.04
Net margin
0.1%

EPS came in at 0.52 against a street estimate of -0.04 — a beat of 1400.0%.

Key statistics

Market cap
$8.22B
P/E
128.9
Forward P/E
133.3
P/B
4.54
Book value
$10.79
EPS (TTM)
$0.38
52-week high
$55.67
52-week low
$25.17
50-day MA
$47.73
200-day MA
$35.50
Beta
0.29

Analyst view

Analysts rate Alkermes Plc a buy (9 buy, 6 hold, 0 sell out of 15) with an average price target of $56.00.

Shareholding

Insiders
1.42%
Institutions
109.01%

Largest institutional holders

FundStake
BlackRock Inc16.88%
Baker Bros Advisors LP5.97%
Vanguard Portfolio Management, LLC5.67%
State Street Corp5.64%
Vanguard Capital Management, LLC4.43%
Renaissance Technologies Corp3.67%
American Century Companies Inc3.62%
T. Rowe Price Associates, Inc.2.78%

Recent filings & reports

DocumentDate
Quarterly report · Q2 20262026-07-28
Results announced · Q3 20262026-07-28
Current report · Q3 20262026-07-08
Reg FD disclosure · Q2 20262026-06-15
Board / officer change · Q2 20262026-05-20
Quarterly report · Q1 20262026-05-05
Proxy statement · Q2 20262026-04-06
Annual report FY20252026-02-25

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Alkermes Plc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.